CymaBay Therapeutics (CBAY) Short Interest Ratio & Short Volume → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free CBAY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability CymaBay Therapeutics Short Interest DataCurrent Short Volume5,850,000 sharesPrevious Short Volume8,370,000 sharesChange Vs. Previous Month-30.11%Dollar Volume Sold Short$188.31 millionShort Interest Ratio / Days to Cover1.6Last Record DateFebruary 29, 2024Outstanding Shares114,724,000 sharesPercentage of Shares Shorted5.10%Today's Trading Volume73 sharesAverage Trading Volume4,113,430 sharesToday's Volume Vs. Average0% Short Selling CymaBay Therapeutics ? Sign up to receive the latest short interest report for CymaBay Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCBAY Short Interest Over TimeCBAY Days to Cover Over TimeCBAY Percentage of Float Shorted Over Time Ad Behind the MarketsBREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.Discover the name and ticker of this $2 stock here >>> CymaBay Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/29/20245,850,000 shares $188.31 million -30.1%N/A1.6 $32.19 2/15/20248,370,000 shares $269.51 million -10.0%N/A2.4 $32.20 1/31/20249,300,000 shares $218.64 million -7.7%N/A5.4 $23.51 1/15/202410,070,000 shares $239.26 million +2.4%N/A5.4 $23.76 12/31/20239,830,000 shares $232.18 million -11.0%N/A5.2 $23.62 12/15/202311,050,000 shares $243.43 million -8.8%N/A5.7 $22.03 Get the Latest News and Ratings for CBAY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/202312,120,000 shares $231.86 million +1.8%N/A5.9 $19.13 11/15/202311,910,000 shares $214.38 million +9.1%N/A5.3 $18.00 10/31/202310,920,000 shares $178.87 million +4.0%N/A4.8 $16.38 10/15/202310,500,000 shares $141.54 million +24.0%N/A5 $13.48 9/30/20238,470,000 shares $126.29 million -8.2%N/A4.1 $14.91 9/15/20239,230,000 shares $152.48 million +3.0%N/A3.9 $16.52 8/31/20238,960,000 shares $123.20 million -21.1%N/A3.7 $13.75 8/15/202311,350,000 shares $145.85 million -0.7%N/A6 $12.85 7/31/202311,430,000 shares $149.16 million -1.0%N/A6.2 $13.05 7/15/202311,540,000 shares $133.75 million -4.6%N/A6.3 $11.59 6/30/202312,100,000 shares $132.50 million +23.5%N/A6.4 $10.95 6/15/20239,800,000 shares $82.42 million +2.7%N/A6 $8.41 5/31/20239,540,000 shares $85.67 million -5.8%N/A6.3 $8.98 5/15/202310,130,000 shares $105.35 million -8.5%N/A6 $10.40 4/30/202311,070,000 shares $119.11 million +7.3%N/A6.8 $10.76 4/15/202310,320,000 shares $91.95 million +6.9%N/A5.7 $8.91 3/31/20239,650,000 shares $84.15 million +26.1%N/A5.6 $8.72 3/15/20237,650,000 shares $69.39 million +54.9%N/A4.7 $9.07 2/28/20234,940,000 shares $39.52 million +11.8%N/A3.6 $8.00 2/15/20234,420,000 shares $35.23 million -0.2%N/A3.5 $7.97 1/31/20234,430,000 shares $37.17 million +17.2%N/A4.1 $8.39 1/15/20233,780,000 shares $24.61 million +1.9%N/A4.5 $6.51 12/30/20223,710,000 shares $23.26 million +7.9%N/A6.2 $6.27 12/15/20223,440,000 shares $14.76 million +11.7%N/A7.4 $4.29 11/30/20223,080,000 shares $10.41 million +5.8%N/A8.2 $3.38 11/15/20222,910,000 shares $10.68 million +60.8%N/A8.2 $3.67 10/31/20221,810,000 shares $6.30 million +4.0%3.1%4.9 $3.48 10/15/20221,740,000 shares $5.78 million +10.1%2.9%4.1 $3.32 9/30/20221,580,000 shares $5.53 million +19.7%2.7%3.2 $3.50 9/15/20221,320,000 shares $5.40 million -27.1%2.2%2 $4.09 8/31/20221,810,000 shares $6.41 million -9.1%3.1%2.5 $3.54 8/15/20221,990,000 shares $8.06 million -36.2%3.4%2.7 $4.05 7/31/20223,120,000 shares $9.77 million -10.9%5.3%3.8 $3.13 7/15/20223,500,000 shares $11.87 million +51.5%5.9%4.2 $3.39Fidelity, Bezos, Goldman Bet Big on Tiny Biotech (Ad)Are you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> CBAY Short Interest - Frequently Asked Questions What is CymaBay Therapeutics' current short interest? Short interest is the volume of CymaBay Therapeutics shares that have been sold short but have not yet been covered or closed out. As of February 29th, investors have sold 5,850,000 shares of CBAY short. Learn More on CymaBay Therapeutics' current short interest. What is a good short interest ratio for CymaBay Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CBAY shares currently have a short interest ratio of 2.0. Learn More on CymaBay Therapeutics's short interest ratio. Is CymaBay Therapeutics' short interest increasing or decreasing? CymaBay Therapeutics saw a decrease in short interest in February. As of February 29th, there was short interest totaling 5,850,000 shares, a decrease of 30.1% from the previous total of 8,370,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does CymaBay Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to CymaBay Therapeutics: Summit Therapeutics Inc. (27.60%), Crinetics Pharmaceuticals, Inc. (6.63%), Biohaven Ltd. (10.10%), Axsome Therapeutics, Inc. (16.32%), Insmed Incorporated (6.33%), Ultragenyx Pharmaceutical Inc. (5.27%), Prestige Consumer Healthcare Inc. (3.72%), HUTCHMED (China) Limited (0.30%), Alkermes plc (7.99%), Perrigo Company plc (2.88%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.39 billion), General Motors ($3.88 billion), Super Micro Computer, Inc. ($3.51 billion), Charter Communications, Inc. ($3.22 billion), Occidental Petroleum Co. ($3.13 billion), Tractor Supply ($2.76 billion), Coinbase Global, Inc. ($2.63 billion), Suncor Energy Inc. ($2.48 billion), Moderna, Inc. ($2.04 billion), and Royal Caribbean Cruises Ltd. ($1.87 billion). View all of the most shorted stocks. What does it mean to sell short CymaBay Therapeutics stock? Short selling CBAY is an investing strategy that aims to generate trading profit from CymaBay Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against CymaBay Therapeutics? A short squeeze for CymaBay Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CBAY, which in turn drives the price of the stock up even further. How often is CymaBay Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CBAY, twice per month. The most recent reporting period available is February, 29 2024. More Short Interest Resources from MarketBeat Related Companies: SMMT Short Interest Data CRNX Short Interest Data BHVN Short Interest Data AXSM Short Interest Data INSM Short Interest Data RARE Short Interest Data PBH Short Interest Data HCM Short Interest Data ALKS Short Interest Data PRGO Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CBAY) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward PressAI “wealth window” is closing June 25thParadigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing